Adipotide
Prohibitin-targeting peptide 1 (Prohibitin-TP01)
Adipotide is a revolutionary experimental vascular-targeting peptidomimetic designed to induce selective apoptosis in blood vessels supplying white adipose tissue. Also known as Prohibitin-TP01, FTPP (Fat-Targeted Proapoptotic Peptide), or TP-1, it represents a completely novel approach to weight management through direct fat cell elimination rather than appetite suppression. While clinical development was discontinued in 2019 due to nephrotoxicity concerns, preclinical studies demonstrated remarkable efficacy with up to 30% weight reduction in rodent models and 11% weight loss in primate studies over just 28 days.
Daily Implementation Guide
Daily Implementation Schedule
Lifestyle Integration Strategies
Nutrition Optimization
- •High-protein meals (30-40g per meal)
- •Eat slowly to enhance satiety effects
- •Stay hydrated (3+ liters daily)
- •Avoid high-fat meals on injection day
Exercise Enhancement
- •Start with 150 min moderate exercise weekly
- •Resistance training 2-3x per week
- •Monitor energy levels during escalation
- •Adjust intensity based on side effects
Sleep & Recovery
- •Maintain consistent sleep schedule
- •Monitor for sleep quality improvements
- •Track energy levels throughout day
- •Adjust injection timing if affecting sleep
Progress Tracking
SUCCESS MILESTONES
Medical Disclaimer
CRITICAL WARNING: Adipotide clinical development was permanently discontinued due to unacceptable nephrotoxicity. All human trials were terminated early. This information is for educational purposes only. Adipotide is NOT approved for any human use and carries severe kidney damage risks. Consult healthcare providers for approved weight management alternatives.